Reference — Renal · Pharmacology
Renal Medication Adjustments Reference
Drug dosing in CKD — medications contraindicated in renal failure, drugs requiring dose adjustment by eGFR threshold, agents that accumulate causing toxicity (digoxin, opioids, enoxaparin, gabapentin, DOACs), and key nursing monitoring priorities for pharmacology and renal nursing.
Reference · Renal · Pharmacology
Educational use only. Drug dosing in CKD is complex and institution-specific. Always consult pharmacy and current prescribing information. eGFR thresholds are approximate — clinical judgment and patient-specific factors apply. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Why CKD Alters Drug Dosing
The kidneys eliminate drugs and metabolites via filtration, secretion, and reabsorption. In CKD, glomerular filtration rate declines → renally-cleared drugs accumulate → toxicity at standard doses. Additionally: uremia alters protein binding (acidic drugs compete with organic acids → more free drug), changes volume of distribution (fluid overload → dilutes drugs), and impairs drug metabolism. Nursing vigilance: review eGFR before administering potentially nephrotoxic or renally-cleared drugs; report unexpected toxicity signs in CKD patients.
Drugs Contraindicated or Avoided in CKD
Metformin
Threshold: Hold if eGFR < 30. Caution 30–45. Safe ≥ 45 mL/min.
| Why Dangerous | Metformin itself is not nephrotoxic but is renally cleared. Accumulation → lactic acidosis (rare but life-threatening). |
| Nursing Action | Hold 48h before iodinated contrast. Restart after contrast only if creatinine stable. Check eGFR before initiating and periodically thereafter. |
NSAIDs (ibuprofen, naproxen, ketorolac, indomethacin)
Threshold: Avoid in moderate-severe CKD (eGFR < 30). Use caution eGFR 30–60.
| Why Dangerous | Prostaglandin inhibition → renal vasoconstriction → AKI. Also cause sodium/water retention (worsens edema and hypertension). Analgesic nephropathy with chronic use. |
| Nursing Action | Suggest acetaminophen as safer alternative for pain in CKD. If NSAID needed for brief course, ensure adequate hydration and monitor creatinine. |
Magnesium-containing antacids / laxatives
Threshold: Avoid in CKD Stage 3b+ (eGFR < 45).
| Why Dangerous | Kidneys excrete excess magnesium. In CKD, magnesium accumulates → hypermagnesemia → respiratory depression, cardiac arrest at severe levels (> 6 mEq/L). |
| Nursing Action | Avoid Maalox, Milk of Magnesia, and magnesium-containing laxatives. Use non-magnesium alternatives (calcium carbonate antacids, polyethylene glycol laxatives). |
Potassium-sparing diuretics (spironolactone, eplerenone) without close monitoring
Threshold: Use extreme caution if eGFR < 30. Avoid in severe hyperkalemia.
| Why Dangerous | Block aldosterone → potassium retention. Combined with ACE/ARBs in CKD = high hyperkalemia risk (K+ > 6.5 mEq/L = risk of fatal arrhythmia). |
| Nursing Action | Monitor potassium closely (q1–2 weeks when initiating or dose-changing). Withhold if K+ > 5.0–5.5 mEq/L per provider protocol. |
Gadolinium contrast (MRI) in severe CKD
Threshold: Avoid if eGFR < 30. Use with caution 30–60.
| Why Dangerous | Nephrogenic systemic fibrosis (NSF) — rare but devastating systemic fibrosis of skin, joints, and organs in patients with severe CKD or ESRD. |
| Nursing Action | Confirm eGFR before gadolinium-enhanced MRI. Alert radiologist if CKD present. Document eGFR in radiology order. Group II (high-risk) gadolinium agents contraindicated in eGFR < 30. |
Oral phosphate bowel prep (Fleets, OsmoPrep, Visicol)
Threshold: Contraindicated in CKD Stage 3+ (eGFR < 60).
| Why Dangerous | Acute phosphate nephropathy — massive phosphorus load → calcium-phosphate precipitation in tubules → irreversible AKI. |
| Nursing Action | Use polyethylene glycol (GoLYTELY) for bowel prep in CKD patients. Verify prep type ordered for patients with CKD before colonoscopy. |
Drugs Requiring Dose Adjustment in CKD
Digoxin
| Adjustment | Reduce dose. Start 0.125 mg every other day in CKD Stage 4–5; very low doses in ESRD. |
| Accumulation Risk | Renally cleared — accumulates to toxic levels. Narrow therapeutic index (0.5–0.9 ng/mL preferred in HF). |
| Monitoring | Digoxin level (trough), potassium level (hypokalemia potentiates toxicity), ECG. Signs of toxicity: bradycardia, nausea/vomiting, visual disturbances (yellow-green halos), confusion. |
| Nursing Notes | Hold if heart rate < 60/min (bradycardia). Report digoxin level above therapeutic range. Treat hypokalemia aggressively (low K+ dramatically increases digoxin toxicity). |
Enoxaparin (Lovenox) — LMWH
| Adjustment | eGFR < 30: reduce dose 50% (treat: 1 mg/kg q24h instead of 1 mg/kg q12h; prophylaxis: 30mg qday). Consider UFH in ESRD (not renally cleared). |
| Accumulation Risk | Renally cleared — anti-Xa accumulates in CKD → increased bleeding risk. |
| Monitoring | Anti-Xa levels (peak, 4h post-dose) if eGFR < 30 and using therapeutically. CBC for bleeding signs. |
| Nursing Notes | Do NOT use standard dosing in CKD without provider adjustment. Suggest unfractionated heparin (UFH) as alternative for ESRD (reversible with protamine, not renally cleared). |
Gabapentin / Pregabalin
| Adjustment | Aggressive dose reduction by eGFR. Gabapentin: eGFR 15–29 → 300 mg daily max; eGFR < 15 → 300 mg every other day. Dialysis: supplement dose after each session. |
| Accumulation Risk | Both 100% renally cleared. Standard doses cause profound CNS toxicity in CKD: encephalopathy, myoclonus, sedation. |
| Monitoring | Neurological status. Sedation. Myoclonic jerks. Encephalopathy in CKD on gabapentin may be confused with uremic encephalopathy. |
| Nursing Notes | Gabapentin toxicity in CKD is common and often missed. Report new confusion, excessive sedation, or myoclonus in renal patients on gabapentin. Dose dialyzed out — post-dialysis supplemental dose often needed. |
Morphine / Codeine
| Adjustment | AVOID in significant CKD (eGFR < 30). If used: reduce dose 50–75% and extend intervals. |
| Accumulation Risk | Morphine-6-glucuronide (M6G) — active toxic metabolite — accumulates → respiratory depression, CNS toxicity, prolonged sedation. Codeine: metabolized to morphine in CYP2D6-competent patients. |
| Monitoring | Respiratory rate, sedation level, pain score. M6G toxicity can occur days after initiation in CKD. |
| Nursing Notes | Prefer fentanyl (CKD-safe opioid — inactive metabolites) or hydromorphone (use with caution, reduced dose) over morphine. Report decreased RR < 12 or excessive sedation. Have naloxone available. |
Oxycodone
| Adjustment | Reduce dose 25–50% in eGFR 10–60. Avoid in ESRD or use very low doses with monitoring. |
| Accumulation Risk | Oxymorphone (active metabolite) accumulates in renal failure → CNS and respiratory depression. |
| Monitoring | Sedation, respiratory rate, pain control. Extended-release formulations especially risky in CKD. |
| Nursing Notes | Avoid long-acting oxycodone (OxyContin) in CKD. Prefer short-acting with dose adjustment. Fentanyl is the safest opioid in CKD. |
Allopurinol (for gout)
| Adjustment | Reduce dose: eGFR 60–90 → 200 mg/day max; eGFR 10–60 → 100 mg/day; eGFR < 10 → 100 mg every 48–72h. |
| Accumulation Risk | Oxypurinol (active metabolite) accumulates → allopurinol hypersensitivity syndrome, Stevens-Johnson syndrome. |
| Monitoring | CBC, LFTs, creatinine, rash surveillance. |
| Nursing Notes | Report any skin rash immediately — allopurinol hypersensitivity syndrome can be life-threatening (DRESS syndrome, SJS/TEN). |
Antibiotics (many require adjustment)
| Adjustment | See specific antibiogram/ID guidelines. Common: Penicillin G reduce dose; ampicillin reduce if eGFR < 10; piperacillin-tazobactam reduce; meropenem reduce; ciprofloxacin reduce frequency; TMP-SMX avoid if eGFR < 15. |
| Accumulation Risk | Many antibiotics renally cleared. Dose/interval adjustments based on eGFR. |
| Monitoring | Drug levels (vancomycin AUC, aminoglycoside peak/trough). Renal function during therapy. |
| Nursing Notes | Always verify antibiotic dosing with pharmacy when patient has CKD. Adjust doses based on current eGFR, not historical baseline. Aminoglycosides + vancomycin = very high nephrotoxicity risk. |
DOACs — Direct Oral Anticoagulants
| Adjustment | Varies by agent: Apixaban (Eliquis): safest in CKD — reduces dose per label criteria. Rivaroxaban (Xarelto): avoid if eGFR < 15. Dabigatran (Pradaxa): CONTRAINDICATED in ESRD. Edoxaban: reduce dose if eGFR < 50. |
| Accumulation Risk | All DOACs partially to fully renally cleared. Accumulation = increased bleeding risk. No reversal agent for all (andexanet alfa reverses Xa inhibitors; idarucizumab reverses dabigatran). |
| Monitoring | Renal function checks q6–12 months. Bleeding signs. Anti-Xa levels if available. |
| Nursing Notes | Apixaban preferred DOAC in CKD. Warfarin or UFH/LMWH typically preferred in ESRD (well-established dosing protocols). Always verify DOAC dosing in pharmacy — provider errors common. |
NCLEX Pearls
Metformin: hold if eGFR < 30 (lactic acidosis risk). Hold before and 48h after contrast. Resume only if creatinine stable.
NSAIDs are dangerous in CKD — cause AKI via renal vasoconstriction. Recommend acetaminophen instead.
Digoxin toxicity signs: bradycardia + nausea + visual changes (yellow-green halos). Hypokalemia dramatically worsens toxicity.
Morphine: AVOID in CKD — toxic metabolite M6G accumulates → respiratory depression. Fentanyl is the safest opioid in renal failure.
Gabapentin toxicity in CKD: encephalopathy, myoclonus, excessive sedation. Renally cleared — standard doses cause toxicity.
Enoxaparin in CKD (eGFR < 30): reduce dose 50% or switch to unfractionated heparin (UFH).
Oral phosphate bowel preps (Fleet, OsmoPrep) CONTRAINDICATED in CKD — use GoLYTELY instead.
Always check eGFR before giving potentially nephrotoxic drugs. The nurse is the last safety check before administration.
Related Resources
Standards & sources
Fact-checked Jun 21, 2026This page is written to align with KDIGO Clinical Practice Guidelines · National Kidney Foundation (NKF). It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →